Oculis News and Activities
Executives
View the org chart displaying its 18 main executives
Most searched biographies at Oculis
- Riad Sherif, Chief Executive Officer and Director
- Anthony Rosenberg, Chairman of the Board
- Geraldine O'Keeffe, Director
Popular executive movements at Oculis
- Gregory Perry has joined the company as Director (posted on May 15 2026).
- Katie Kazem has joined the company as Chief Legal Officer (posted on February 17 2026).
Create your alert
to follow the executive moves at Oculis.
Pharmaceuticals
Oculis has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
- Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Oculis
- Oculis Reports Q3 2023 Financial Results and Provides Company Update | Oculis
- News Releases | Oculis
- Oculis to Present at Upcoming November Investor Conferences | Oculis
- Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema | Oculis
- Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema | Oculis
- Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress | Oculis
- Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase | Oculis
- Oculis to Present at Upcoming September Investor Conferences | Oculis
- Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update | Oculis
- OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery | Oculis
- View more press releases Close
Social media about Oculis
- Oculis on Wikipedia, Google News & Yahoo Finance
- Oculis on LinkedIn, X (Twitter) & YouTube
